Directorio

The purpose of this study is to understand the safety of IDE196 when given before and after treatment.

We are doing this study to compare the outcomes of people who get their after-transplant care in the hospital versus in their home. This study is important to learn if getting after-transplant care in a patient's home can lead to better outcomes.

We are doing this study to find out if an experimental drug called IMM-1-104 (the study drug) is a safe and effective option for patients with melanoma, pancreatic cancer, or lung cancer. We also want to find out what dose of the study drug works best.

We are doing this study to test a program that is designed to help young cancer survivors improve how well they follow diet and exercise guidelines, manage their weight, and cope with physical and emotional symptoms that can interfere with diet, exercise, and weight management.

We are doing this study to find the most effective, safe dose of an experimental drug called INCB000928 (the study drug). We want to know how well this study drug works alone and in combination with ruxolitinib in people with anemia due to myeloproliferative disorders.

We are doing this study to find the most effective, safe dose of an experimental drug called INT230-6 (the study drug) in people with recurrent, inoperable, or metastatic soft tissue sarcomas (STS). We also want to know how well it works compared to the usual treatments for people with this diagnosis.

We are doing this study to learn more about prostate cancer and whether certain treatments are related with different outcomes and patient experiences.

We are doing this study to find out if an experimental drug called KTX-1001 (the study drug) is a safe and effective treatment for multiple myeloma. We want to identify the most appropriate dose and dosing schedule of the study drug for patients with multiple myeloma.